DSIP
Delta sleep-inducing peptide (emideltide)
DSIP/emideltide is an experimental peptide with very small, old sleep studies. In 2026 the FDA separately evaluated the free base and acetate for proposed compounding uses.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
DSIP is used for emideltide; the free base and acetate salt are distinct substance forms. Without sequence, salt, purity and aggregation data, a product identity is not confirmed.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
DSIP is used for emideltide; the free base and acetate salt are distinct substance forms. Without sequence, salt, purity and aggregation data, a product identity is not confirmed.
- Human research
- Very limited
- Replication
- Single research group
- Clinical endpoints
- Surrogate measures
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The cited double-blind investigation included six healthy volunteers. FDA found substantial methodological heterogeneity and no adequate basis for reliable conclusions in chronic insomnia.
- Acute and delayed effects of DSIP on human sleep behaviorHuman study1981
Schneider-Helmert D; Gnirss F; Monnier M; Schenker J; Schoenenberger GA
Accessed:
- FDA evaluation of emideltide-related bulk drug substances (free base and acetate)Regulatory source2026
U.S. Food and Drug Administration
Accessed:
Research gaps
- ·The sample size, age and heterogeneity of the data do not support reliable efficacy conclusions. Pharmacokinetic data for the proposed subcutaneous route were absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
The name “sleep-inducing” does not establish reliable sleep promotion; no clinically validated mechanism has been demonstrated.
- Acute and delayed effects of DSIP on human sleep behaviorHuman study1981
Schneider-Helmert D; Gnirss F; Monnier M; Schenker J; Schoenenberger GA
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. FDA identifies missing toxicology and potential immunogenicity from aggregation and peptide-related impurities, especially with injection.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·The sample size, age and heterogeneity of the data do not support reliable efficacy conclusions. Pharmacokinetic data for the proposed subcutaneous route were absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- FDA evaluation of emideltide-related bulk drug substances (free base and acetate)Regulatory source2026
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 3
- Acute and delayed effects of DSIP on human sleep behaviorHuman study1981
Schneider-Helmert D; Gnirss F; Monnier M; Schenker J; Schoenenberger GA
Accessed:
- FDA evaluation of emideltide-related bulk drug substances (free base and acetate)Regulatory source2026
U.S. Food and Drug Administration
Accessed: